base metals investing Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates
base metals investing Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026
base metals investing Cellectar Biosciences to Highlight Strategic Initiatives for 2026 at Upcoming Biotech Showcase during 44th Annual JP Morgan Healthcare Conference
base metals investing Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies
base metals investing Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update
base metals investing Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Thursday, November 13, 2025
base metals investing Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma
base metals investing Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research Special Conference on Pancreatic Cancer Research
Alvopetro Announces Year End 2025 Financial Results, Q1 2026 Dividend of US$0.12/share, and Filing of our AIF
QIMC Reports Results from Hole 1 DDH-26-01 at West-Advocate Natural Hydrogen Project, Nova Scotia; R2G2(TM) Exploration Model Applied
